<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Day One Biopharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/day-one-biopharmaceuticals-inc</link>
    <description>Latest news and press releases for Day One Biopharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 06 Mar 2026 05:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/day-one-biopharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355bd478dffbe2df0ec104.webp</url>
      <title>Day One Biopharmaceuticals Inc</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc</link>
    </image>
    <item>
      <title>Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-serviers-rare-oncology-portfolio-31</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/servier-and-day-one-biopharmaceuticals-announce-acquisition-to-expand-serviers-rare-oncology-portfolio-31</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high</description>
    </item>
    <item>
      <title>Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026-outlook-and-revenue-guidance</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026-outlook-and-revenue-guidance</guid>
      <pubDate>Tue, 24 Feb 2026 21:00:00 GMT</pubDate>
      <description>OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day</description>
    </item>
    <item>
      <title>Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-fourth-quarter-133000466</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-fourth-quarter-133000466</guid>
      <pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
      <description>BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025. Live audio of the</description>
    </item>
    <item>
      <title>Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-announces-preliminary-2025-ojemdatm-net-product-revenue-and-provides-2026-net</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-announces-preliminary-2025-ojemdatm-net-product-revenue-and-provides-2026-net</guid>
      <pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
      <description>Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 -</description>
    </item>
    <item>
      <title>Day One Completes Acquisition of Mersana Therapeutics</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-completes-acquisition-mersana-therapeutics-2026-01-06</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-completes-acquisition-mersana-therapeutics-2026-01-06</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting rare cancer adenoid cystic</description>
    </item>
    <item>
      <title>Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-present-44th-annual-jp-morgan-healthcare-conference-2025-12-16</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-present-44th-annual-jp-morgan-healthcare-conference-2025-12-16</guid>
      <pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
      <description>BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company</description>
    </item>
    <item>
      <title>Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-announces-three-year-follow-data-ojemdatm-tovorafenib-phase-2-firefly-1-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-announces-three-year-follow-data-ojemdatm-tovorafenib-phase-2-firefly-1-trial</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period</description>
    </item>
    <item>
      <title>Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-participate-piper-sandler-37th-annual-healthcare-conference-2025-11-18</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-participate-piper-sandler-37th-annual-healthcare-conference-2025-11-18</guid>
      <pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
      <description>BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company</description>
    </item>
    <item>
      <title>Day One Biopharmaceuticals to Acquire Mersana Therapeutics</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-biopharmaceuticals-acquire-mersana-110000815</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-biopharmaceuticals-acquire-mersana-110000815</guid>
      <pubDate>Thu, 13 Nov 2025 11:00:00 GMT</pubDate>
      <description>Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million Closing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug</description>
    </item>
    <item>
      <title>Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-acquire-mersana-therapeutics-advance-mission-bring-new-medicines-people-all</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-acquire-mersana-therapeutics-advance-mission-bring-new-medicines-people-all</guid>
      <pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
      <description>Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor</description>
    </item>
    <item>
      <title>Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-announces-new-ojemdatm-tovorafenib-data-be-presented-oral-session-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-announces-new-ojemdatm-tovorafenib-data-be-presented-oral-session-2025</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment</description>
    </item>
    <item>
      <title>Day One Reports Third Quarter 2025 Financial Results and Corporate Progress</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-third-quarter-2025-financial-results-and-corporate-progress-2025-11</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-third-quarter-2025-financial-results-and-corporate-progress-2025-11</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue</description>
    </item>
    <item>
      <title>Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-third-quarter-2025-financial-results-tuesday-november-4-2025-2025-10</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-third-quarter-2025-financial-results-tuesday-november-4-2025-2025-10</guid>
      <pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
      <description>BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company</description>
    </item>
    <item>
      <title>Day One Reports Second Quarter 2025 Financial Results and Corporate Progress</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-second-quarter-2025-financial-results-and-corporate-progress-2025-08</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-second-quarter-2025-financial-results-and-corporate-progress-2025-08</guid>
      <pubDate>Tue, 05 Aug 2025 04:00:00 GMT</pubDate>
      <description>OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected</description>
    </item>
    <item>
      <title>Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-second-quarter-2025-financial-results-tuesday-august-5-2025-2025-07-22</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-second-quarter-2025-financial-results-tuesday-august-5-2025-2025-07-22</guid>
      <pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
      <description>BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company</description>
    </item>
    <item>
      <title>Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-appoints-michael-vasconcelles-md-head-research-and-development-2025-06-10</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-appoints-michael-vasconcelles-md-head-research-and-development-2025-06-10</guid>
      <pubDate>Tue, 10 Jun 2025 04:00:00 GMT</pubDate>
      <description>Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive</description>
    </item>
    <item>
      <title>Day One Reports First Quarter 2025 Financial Results and Corporate Progress</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-first-quarter-2025-financial-results-and-corporate-progress-2025-05</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-first-quarter-2025-financial-results-and-corporate-progress-2025-05</guid>
      <pubDate>Tue, 06 May 2025 04:00:00 GMT</pubDate>
      <description>OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended</description>
    </item>
    <item>
      <title>Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-first-quarter-2025-financial-results-tuesday-may-6-2025-2025-04-22</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-first-quarter-2025-financial-results-tuesday-may-6-2025-2025-04-22</guid>
      <pubDate>Tue, 22 Apr 2025 04:00:00 GMT</pubDate>
      <description>BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company</description>
    </item>
    <item>
      <title>Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-fourth-quarter-and-full-year-2024-financial-results-and-corporate</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-reports-fourth-quarter-and-full-year-2024-financial-results-and-corporate</guid>
      <pubDate>Tue, 25 Feb 2025 05:00:00 GMT</pubDate>
      <description>Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7</description>
    </item>
    <item>
      <title>Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025</title>
      <link>https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-fourth-quarter-and-full-year-2024-financial-results-tuesday-february</link>
      <guid isPermaLink="true">https://6ix.com/company/day-one-biopharmaceuticals-inc/news/day-one-report-fourth-quarter-and-full-year-2024-financial-results-tuesday-february</guid>
      <pubDate>Tue, 11 Feb 2025 05:00:00 GMT</pubDate>
      <description>BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company</description>
    </item>
  </channel>
</rss>